WO2019185439A1 - Composition de base naturelle destinée à être utilisée dans le traitement d'un stress chronique, caractérisé par des troubles de l'humeur et/ou de l'anxiété - Google Patents
Composition de base naturelle destinée à être utilisée dans le traitement d'un stress chronique, caractérisé par des troubles de l'humeur et/ou de l'anxiété Download PDFInfo
- Publication number
- WO2019185439A1 WO2019185439A1 PCT/EP2019/057055 EP2019057055W WO2019185439A1 WO 2019185439 A1 WO2019185439 A1 WO 2019185439A1 EP 2019057055 W EP2019057055 W EP 2019057055W WO 2019185439 A1 WO2019185439 A1 WO 2019185439A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- extract
- formulation
- treatment
- use according
- composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 74
- 238000011282 treatment Methods 0.000 title claims abstract description 70
- 208000019901 Anxiety disease Diseases 0.000 title claims abstract description 67
- 208000019022 Mood disease Diseases 0.000 title claims abstract description 26
- 230000036651 mood Effects 0.000 title description 26
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 claims abstract description 54
- 239000000284 extract Substances 0.000 claims abstract description 45
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 claims abstract description 34
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 claims abstract description 34
- 229960003987 melatonin Drugs 0.000 claims abstract description 34
- 241000218378 Magnolia Species 0.000 claims abstract description 30
- 239000001599 crocus sativus l. flower extract Substances 0.000 claims abstract description 30
- 229940076591 saffron extract Drugs 0.000 claims abstract description 30
- 238000009472 formulation Methods 0.000 claims abstract description 25
- DATAGRPVKZEWHA-UHFFFAOYSA-N L-gamma-glutamyl-n-ethylamine Natural products CCNC(=O)CCC(N)C(O)=O DATAGRPVKZEWHA-UHFFFAOYSA-N 0.000 claims abstract description 24
- 229940094952 green tea extract Drugs 0.000 claims abstract description 22
- 235000020688 green tea extract Nutrition 0.000 claims abstract description 22
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 9
- 230000002265 prevention Effects 0.000 claims abstract description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 8
- 239000011248 coating agent Substances 0.000 claims description 13
- 238000000576 coating method Methods 0.000 claims description 13
- 239000008187 granular material Substances 0.000 claims description 12
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 10
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 10
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 10
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 8
- 239000008240 homogeneous mixture Substances 0.000 claims description 7
- 239000000975 dye Substances 0.000 claims description 4
- 239000000377 silicon dioxide Substances 0.000 claims description 4
- 235000012239 silicon dioxide Nutrition 0.000 claims description 4
- 229940026510 theanine Drugs 0.000 claims description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 3
- 239000001692 EU approved anti-caking agent Substances 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 3
- 235000010980 cellulose Nutrition 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 230000003111 delayed effect Effects 0.000 claims description 3
- 239000000796 flavoring agent Substances 0.000 claims description 3
- 235000019634 flavors Nutrition 0.000 claims description 3
- 235000003599 food sweetener Nutrition 0.000 claims description 3
- 239000003701 inert diluent Substances 0.000 claims description 3
- 239000000314 lubricant Substances 0.000 claims description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
- 239000003765 sweetening agent Substances 0.000 claims description 3
- 239000002562 thickening agent Substances 0.000 claims description 3
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 230000036506 anxiety Effects 0.000 description 43
- 239000003826 tablet Substances 0.000 description 36
- 239000004480 active ingredient Substances 0.000 description 28
- 230000000694 effects Effects 0.000 description 26
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 22
- 244000124209 Crocus sativus Species 0.000 description 17
- 235000015655 Crocus sativus Nutrition 0.000 description 16
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 14
- 229940079593 drug Drugs 0.000 description 14
- 239000003814 drug Substances 0.000 description 14
- 230000006872 improvement Effects 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 230000009467 reduction Effects 0.000 description 13
- VVOAZFWZEDHOOU-UHFFFAOYSA-N honokiol Natural products OC1=CC=C(CC=C)C=C1C1=CC(CC=C)=CC=C1O VVOAZFWZEDHOOU-UHFFFAOYSA-N 0.000 description 12
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 229940030275 epigallocatechin gallate Drugs 0.000 description 11
- 235000013974 saffron Nutrition 0.000 description 11
- 239000004248 saffron Substances 0.000 description 11
- 229940076279 serotonin Drugs 0.000 description 11
- 208000019116 sleep disease Diseases 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 10
- 230000035882 stress Effects 0.000 description 9
- 244000269722 Thea sinensis Species 0.000 description 8
- 239000000935 antidepressant agent Substances 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 235000013305 food Nutrition 0.000 description 8
- 208000020401 Depressive disease Diseases 0.000 description 7
- 230000009471 action Effects 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- PANKHBYNKQNAHN-JTBLXSOISA-N Crocetin Natural products OC(=O)C(\C)=C/C=C/C(/C)=C\C=C\C=C(\C)/C=C/C=C(/C)C(O)=O PANKHBYNKQNAHN-JTBLXSOISA-N 0.000 description 6
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 230000001430 anti-depressive effect Effects 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 6
- PANKHBYNKQNAHN-JUMCEFIXSA-N carotenoid dicarboxylic acid Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C(=O)O)C=CC=C(/C)C(=O)O PANKHBYNKQNAHN-JUMCEFIXSA-N 0.000 description 6
- PANKHBYNKQNAHN-MQQNZMFNSA-N crocetin Chemical compound OC(=O)C(/C)=C/C=C/C(/C)=C/C=C/C=C(\C)/C=C/C=C(\C)C(O)=O PANKHBYNKQNAHN-MQQNZMFNSA-N 0.000 description 6
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
- 235000009569 green tea Nutrition 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 206010022437 insomnia Diseases 0.000 description 6
- 239000002207 metabolite Substances 0.000 description 6
- SGAWOGXMMPSZPB-UHFFFAOYSA-N safranal Chemical compound CC1=C(C=O)C(C)(C)CC=C1 SGAWOGXMMPSZPB-UHFFFAOYSA-N 0.000 description 6
- 230000007958 sleep Effects 0.000 description 6
- SEBIKDIMAPSUBY-ARYZWOCPSA-N Crocin Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)C(C)=CC=CC(C)=C\C=C\C=C(/C)\C=C\C=C(C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1)O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SEBIKDIMAPSUBY-ARYZWOCPSA-N 0.000 description 5
- SEBIKDIMAPSUBY-JAUCNNNOSA-N Crocin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C(=O)OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C=CC=C(/C)C(=O)OC3OC(COC4OC(CO)C(O)C(O)C4O)C(O)C(O)C3O SEBIKDIMAPSUBY-JAUCNNNOSA-N 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 229940005513 antidepressants Drugs 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 235000021466 carotenoid Nutrition 0.000 description 5
- 150000001747 carotenoids Chemical class 0.000 description 5
- 230000003001 depressive effect Effects 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 229930003935 flavonoid Natural products 0.000 description 5
- 235000017173 flavonoids Nutrition 0.000 description 5
- 150000002215 flavonoids Chemical class 0.000 description 5
- 239000002858 neurotransmitter agent Substances 0.000 description 5
- 230000036542 oxidative stress Effects 0.000 description 5
- -1 saffron Chemical class 0.000 description 5
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 4
- 206010002869 Anxiety symptoms Diseases 0.000 description 4
- 206010054089 Depressive symptom Diseases 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- BYTORXDZJWWIKR-UHFFFAOYSA-N Hinokiol Natural products CC(C)c1cc2CCC3C(C)(CO)C(O)CCC3(C)c2cc1O BYTORXDZJWWIKR-UHFFFAOYSA-N 0.000 description 4
- 241001673966 Magnolia officinalis Species 0.000 description 4
- 206010028813 Nausea Diseases 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 230000006399 behavior Effects 0.000 description 4
- 150000001765 catechin Chemical class 0.000 description 4
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 4
- 235000005487 catechin Nutrition 0.000 description 4
- 230000002490 cerebral effect Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- FVYXIJYOAGAUQK-UHFFFAOYSA-N honokiol Chemical compound C1=C(CC=C)C(O)=CC=C1C1=CC(CC=C)=CC=C1O FVYXIJYOAGAUQK-UHFFFAOYSA-N 0.000 description 4
- 230000008693 nausea Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000035807 sensation Effects 0.000 description 4
- 235000019615 sensations Nutrition 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 231100000027 toxicology Toxicity 0.000 description 4
- 229930014124 (-)-epigallocatechin gallate Natural products 0.000 description 3
- 235000004911 (-)-epigallocatechin gallate Nutrition 0.000 description 3
- 206010001497 Agitation Diseases 0.000 description 3
- 206010008479 Chest Pain Diseases 0.000 description 3
- 206010022998 Irritability Diseases 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 206010044565 Tremor Diseases 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- SEBIKDIMAPSUBY-UHFFFAOYSA-N bis[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl] 2,6,11,15-tetramethylhexadeca-2,4,6,8,10,12,14-heptaenedioate Chemical class O1C(COC2C(C(O)C(O)C(CO)O2)O)C(O)C(O)C(O)C1OC(=O)C(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C(=O)OC(C(C(O)C1O)O)OC1COC1OC(CO)C(O)C(O)C1O SEBIKDIMAPSUBY-UHFFFAOYSA-N 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000001914 calming effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 239000001209 crocus sativus l. Substances 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 3
- 230000002996 emotional effect Effects 0.000 description 3
- VFSWRBJYBQXUTE-UHFFFAOYSA-N epi-Gallocatechin 3-O-gallate Natural products Oc1ccc2C(=O)C(OC(=O)c3cc(O)c(O)c(O)c3)C(Oc2c1)c4cc(O)c(O)c(O)c4 VFSWRBJYBQXUTE-UHFFFAOYSA-N 0.000 description 3
- 230000002964 excitative effect Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 229960002748 norepinephrine Drugs 0.000 description 3
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 3
- 230000008447 perception Effects 0.000 description 3
- 150000008442 polyphenolic compounds Chemical class 0.000 description 3
- 235000013824 polyphenols Nutrition 0.000 description 3
- 235000017509 safranal Nutrition 0.000 description 3
- 230000003860 sleep quality Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- 230000036642 wellbeing Effects 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical group CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 206010016352 Feeling of relaxation Diseases 0.000 description 2
- 102000004300 GABA-A Receptors Human genes 0.000 description 2
- 108090000839 GABA-A Receptors Proteins 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 235000017309 Hypericum perforatum Nutrition 0.000 description 2
- 208000037490 Medically Unexplained Symptoms Diseases 0.000 description 2
- 102000010909 Monoamine Oxidase Human genes 0.000 description 2
- 108010062431 Monoamine oxidase Proteins 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 206010041349 Somnolence Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 208000001871 Tachycardia Diseases 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000002249 anxiolytic agent Substances 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000027288 circadian rhythm Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- CZNNQWMLAHSKRA-NVAFIHLTSA-N dTDP 1-ester with 2,6-dideoxy-L-erythro-hexopyranos-3-ulose Chemical compound C1C(=O)[C@@H](O)[C@H](C)O[C@@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)C[C@H](N2C(NC(=O)C(C)=C2)=O)O1 CZNNQWMLAHSKRA-NVAFIHLTSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 206010013781 dry mouth Diseases 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000003371 gabaergic effect Effects 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 231100000025 genetic toxicology Toxicity 0.000 description 2
- 230000001738 genotoxic effect Effects 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- 230000000862 serotonergic effect Effects 0.000 description 2
- 208000013220 shortness of breath Diseases 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 229910021653 sulphate ion Inorganic materials 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000007916 tablet composition Substances 0.000 description 2
- 230000006794 tachycardia Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- LDCYZAJDBXYCGN-UHFFFAOYSA-N 5-hydroxytryptophan Chemical compound C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 description 1
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 1
- TWCMVXMQHSVIOJ-UHFFFAOYSA-N Aglycone of yadanzioside D Natural products COC(=O)C12OCC34C(CC5C(=CC(O)C(O)C5(C)C3C(O)C1O)C)OC(=O)C(OC(=O)C)C24 TWCMVXMQHSVIOJ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002758 Anticipatory anxiety Diseases 0.000 description 1
- 206010002942 Apathy Diseases 0.000 description 1
- PLMKQQMDOMTZGG-UHFFFAOYSA-N Astrantiagenin E-methylester Natural products CC12CCC(O)C(C)(CO)C1CCC1(C)C2CC=C2C3CC(C)(C)CCC3(C(=O)OC)CCC21C PLMKQQMDOMTZGG-UHFFFAOYSA-N 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102100040999 Catechol O-methyltransferase Human genes 0.000 description 1
- 108020002739 Catechol O-methyltransferase Proteins 0.000 description 1
- 108010004103 Chylomicrons Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 101000874334 Dalbergia nigrescens Isoflavonoid 7-O-beta-apiosyl-glucoside beta-glycosidase Proteins 0.000 description 1
- 206010011971 Decreased interest Diseases 0.000 description 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
- 206010013496 Disturbance in attention Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 101000757733 Enterococcus faecalis (strain ATCC 700802 / V583) Autolysin Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 206010016275 Fear Diseases 0.000 description 1
- 102000027484 GABAA receptors Human genes 0.000 description 1
- 108091008681 GABAA receptors Proteins 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 102000058063 Glucose Transporter Type 1 Human genes 0.000 description 1
- 241000219774 Griffonia Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 241000546188 Hypericum Species 0.000 description 1
- 244000141009 Hypericum perforatum Species 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
- 208000017657 Menopausal disease Diseases 0.000 description 1
- 241000551546 Minerva Species 0.000 description 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
- 206010027940 Mood altered Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- 206010028403 Mutism Diseases 0.000 description 1
- 101000757734 Mycolicibacterium phlei 38 kDa autolysin Proteins 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033664 Panic attack Diseases 0.000 description 1
- 241000972672 Phellodendron Species 0.000 description 1
- 241000972673 Phellodendron amurense Species 0.000 description 1
- 229930182780 Polyphenon E Natural products 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 108091006296 SLC2A1 Proteins 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000004383 Steviol glycoside Substances 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010043275 Teratogenicity Diseases 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 235000001667 Vitex agnus castus Nutrition 0.000 description 1
- 244000063464 Vitex agnus-castus Species 0.000 description 1
- 208000021017 Weight Gain Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000037328 acute stress Effects 0.000 description 1
- 230000006389 acute stress response Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 229960004538 alprazolam Drugs 0.000 description 1
- 229940025131 amylases Drugs 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 1
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 1
- 229940117893 apigenin Drugs 0.000 description 1
- 235000008714 apigenin Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000002425 cardiocirculatory effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 201000003104 endogenous depression Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 208000037870 generalized anxiety Diseases 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- PFOARMALXZGCHY-UHFFFAOYSA-N homoegonol Natural products C1=C(OC)C(OC)=CC=C1C1=CC2=CC(CCCO)=CC(OC)=C2O1 PFOARMALXZGCHY-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 239000000399 hydroalcoholic extract Substances 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- BTXNYTINYBABQR-UHFFFAOYSA-N hypericin Chemical compound C12=C(O)C=C(O)C(C(C=3C(O)=CC(C)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 BTXNYTINYBABQR-UHFFFAOYSA-N 0.000 description 1
- 229940005608 hypericin Drugs 0.000 description 1
- PHOKTTKFQUYZPI-UHFFFAOYSA-N hypericin Natural products Cc1cc(O)c2c3C(=O)C(=Cc4c(O)c5c(O)cc(O)c6c7C(=O)C(=Cc8c(C)c1c2c(c78)c(c34)c56)O)O PHOKTTKFQUYZPI-UHFFFAOYSA-N 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000003715 limbic system Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 230000001343 mnemonic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000000302 molecular modelling Methods 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000008452 non REM sleep Effects 0.000 description 1
- 229940053480 non-selective monoamine reuptake inhibitors Drugs 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 235000009048 phenolic acids Nutrition 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 208000019899 phobic disease Diseases 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 210000004560 pineal gland Anatomy 0.000 description 1
- 230000008635 plant growth Effects 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 210000005215 presynaptic neuron Anatomy 0.000 description 1
- SSKVDVBQSWQEGJ-UHFFFAOYSA-N pseudohypericin Natural products C12=C(O)C=C(O)C(C(C=3C(O)=CC(O)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 SSKVDVBQSWQEGJ-UHFFFAOYSA-N 0.000 description 1
- 238000001671 psychotherapy Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 231100000101 reproductive and developmental toxicity testing Toxicity 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
- 230000000697 serotonin reuptake Effects 0.000 description 1
- 230000002295 serotoninergic effect Effects 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 231100001251 short-term toxicity Toxicity 0.000 description 1
- 231100000438 skin toxicity Toxicity 0.000 description 1
- 230000037321 sleepiness Effects 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000014268 sports nutrition Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 235000019411 steviol glycoside Nutrition 0.000 description 1
- 229930182488 steviol glycoside Natural products 0.000 description 1
- 150000008144 steviol glycosides Chemical class 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 231100000211 teratogenicity Toxicity 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 235000020795 whole food diet Nutrition 0.000 description 1
- 230000005186 women's health Effects 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
- 230000031143 xenobiotic glucuronidation Effects 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
Definitions
- the present invention relates to the field of pharmaceutical and food supplement industry.
- the invention relates to a natural base composition for mood regulation, the prevention and/or treatment of mood and/or anxiety disorders.
- migraine disorder refers to a large class of mood alteration symptoms of the individual, as well as to maladaptation to relational and environmental life conditions, influencing the interpersonal and/or working sphere.
- Depression is among the most recurring mood disorders, namely a form of mental suffering characterized by lowering of mood.
- the“unipolar depression” is associated with events wherein a high emotional stress is involved and is typically accompanied by anxiety and agitation symptoms.
- Depression may occur in different ways assuming different aspects in relation to such factors as age, personality and causes. There is a considerable mental and motor involvement in the most serious forms up to the melancholic stupor with mutism and immobility. More rarely, states of restlessness and excitement based on a considerable anxious component may be observed. When depression is associated with irritability, bad mood and aggression, such a condition is known as “dysphoria”.
- the depressive state comprises mental, psychomotor and somatic manifestations. This results in a condition of suffering and pain, which appears with sadness, pessimism, slowing down of ideation and motor activity, reduction in self-evaluation and self-confidence, loss of interests, difficulty in performing the usual activities, tendency to cry.
- anxiety namely a mental state characterized by a sensation of fear which is not connected to any specific stimulus
- anxiety is often accompanied by different physical conditions, such, for example, palpitations, chest pains, shortness of breath, nausea and tremor.
- anxiety causes a sense of terror or panic, nausea and shivers.
- behavioural point of view both voluntary and involuntary behaviours may occur, aimed at escaping or avoiding the source of anxiety; these behaviours are recurring and often not adaptive, since they are extreme in anxiety disorders.
- generalized anxiety manifestations such as a state of excessive anxiety without any manifest or clear reasons, may be distinguished in case of pathological anxiety disorder; panic attacks, such as sudden unbearable fear attacks, appear along with pronounced somatic symptoms, such as sweating, tachycardia, chest pain, tremor, suffocating sensation; phobias, namely strong fears of objects and specific situations; obsessive-compulsive disorders, namely ritual compulsive behaviours caused by irrational anxiety.
- insomnia As for sleep disorders, it is known that, typically, such disorders usually lead to the development of insomnia, characterized by a difficulty in falling asleep and sleep continuity and in general by a not refreshing sleep.
- Insomnia may cause discomfort also during the day; in fact, patients often experience attention difficulties, poor concentration and memory deficiency, irritability, energy reduction, daytime sleepiness, generic fatigue sensation and discomfort.
- Anxiety and sleeping disorders, as well as other diseases caused by depression, are typically alleviated when the patient take drugs which directly act on the depressive state, the so-called “antidepressant medicines”.
- the most common antidepressant drugs are represented by selective serotonin reuptake inhibitors, selective noradrenaline reuptake inhibitors, monoamine oxidase enzyme inhibitors (an enzyme which decomposes monoamines), non-selective monoamine reuptake inhibitors and non-selective receptor antagonists.
- drugs may result to be dangerous if overdosed and, furthermore, they may interact with other drugs, such as anaesthetic, anti-hypertensive and non-steroidal anti-inflammatory drugs.
- the antidepressant drugs need at least two weeks to bring about some beneficial effects even if their pharmacological effects are immediately produced, which indicates that the adaptive secondary modifications play an important role.
- a further relevant aspect regards the intake of drugs, for example sleep- inducing/ anxiolytic and antidepressant drugs, even if the pathological conditions of the patient do not necessarily require the use thereof. This may result in pharmacological dependency manifestations in such specific patients, more often due to sleep-inducing drugs.
- drugs for example sleep- inducing/ anxiolytic and antidepressant drugs
- the consumption of the extract of the Hypericum officinal plant involves benefits for the reduction of anxiety, melancholy and sleep disorders.
- These properties are mainly ascribed to flavonoids, in particular to hypericin, contained in the extract of such a plant which carry out an antidepressant action in case of mood alterations.
- griffonia Grifforda simplicifolia
- 5-hydroxy-tryptophan 5-hydroxy-tryptophan
- Patent application ES 2573542 describes a powder composition comprising the saffron stigma extract for therapeutic use, in particular for the treatment of mood disorders related to depression.
- Patent application US 2005/0208156 describes the use of different compounds, such as saffron, for the treatment of schizophrenia; saffron can be used both fresh and in the dried form, all parts or only some thereof depending on the plant growth stage may be used and preferably the stigma extract is used.
- US 2017/239312 describes a weight loss system , which comprises a weight loss accelerator formulation, comprising different active ingredients, such as saffron, and a weight loss control formulation , comprising, among other active ingredients , green tea and L-theanine extract.
- US 201 1/014277 describes a composition for tobacco smoking cessation , comprising, among other active ingredients, magnolia extract, green tea extract, L-theanine and melatonin.
- US 2006/018975 describes a food supplement composition for the treatment of mood disorders, comprising, among other active ingredients, magnolia bark extract, green tea extract and L-theanine.
- WO 2017/ 182688 describes a saffron extract for the treatment of mood disorders.
- Kaylynn Chiarello-Ebner “Getting a Head Start - A report on the nutritional building blocks for memory and mood support”, Wholefoods Magazine, 2013-06-01 describes a saffron extract and a magnolia extract for use in the treatment of depression.
- the problem underlying the present invention is to provide a composition for the treatment of mood and/or anxiety disorders containing active ingredients of natural origin, having an excellent tolerability, no side effects and an improved action compared to the compositions of the prior art.
- the present invention solves the above-mentioned technical problem by providing a composition comprising 10-20 mg of saffron extract, 50-70 mg of magnolia extract and 180-220 mg of green tea extract for the use in the prevention and treatment of mood disorders and/or anxiety disorders.
- the composition further comprises L-theanine.
- the composition further comprises melatonin.
- the present invention also describes a pharmaceutical or food supplement formulation suitable for oral administration, for the prevention and treatment of mood disorders and/or anxiety disorders, comprising the above-mentioned composition for the above-mentioned use and at least one pharmaceutically or nutritionally acceptable excipient.
- the above-mentioned formulation also comprises 180-220 mg of L-theanine and possibly also 0.5-3.0 mg, preferably 0.5- 1.5 mg of melatonin.
- the at least one pharmaceutically or nutritionally acceptable excipient is selected from the group comprising inert diluents, sweetening agents, flavors, anti-caking agents, lubricants, dyes, film-forming agents, microcrystalline cellulose, cellulose derivatives and thickening agents.
- the formulation according to the present invention is in the form of tablet containing the above-mentioned formulation.
- the tablet comprises an outer coating and an inner core comprising gastro-resistant granules containing said saffron extract and said magnolia extract.
- the gastro-resistant granules comprise polyvinylpyrrolidone and microcrystalline cellulose.
- the inner core further comprises a homogeneous mixture in the form of powder comprising said green tea extract.
- the homogeneous mixture in the form of powder further comprises said L-theanine.
- the homogeneous mixture in the form of powder further comprises further carboxymethylcellulose or salts thereof, microcrystalline cellulose and silicon dioxide.
- the outer coating comprises melatonin.
- the tablet has an inner core containing gastro- resistant granules, comprising saffron extract and magnolia extract, and a powder mixture comprising green tea and theanine extract, as well as an outer coating containing melatonin, and it is characterized in that it has an immediate release of melatonin, followed by a gradual release of green tea extract and theanine and a delayed release of saffron extract and magnolia extract.
- the delayed release of saffron and magnolia extract occurs in the intestine.
- composition of the present invention advantageously comprises different naturally-occurring active ingredients which act in a complementary way and in synergy with each other.
- the saffron extract rich in safranal and crocin exerts a serotoninergic action, thus directly contributing to the increasing of serotonin levels in the organism, thus considerably improving the patient’s mood.
- magnolia extract is provided with tranquilizing , calming properties, because it is able to considerably reduce states of anxiety, sleeping alterations and mood instability.
- the green tea leaves extract rich in catechins, shows an important antioxidant activity and reduces the oxidative stress, to specifically reduce anxiety conditions and sleep disorders.
- this composition advantageously also comprises L-theanine amino acid, which directly affects the noradrenalin, serotonin and dopamine levels in the organism.
- L-theanine s main action is on the anxiety reduction, acting as an antagonist of the excitatory neurotransmitters (for example glutamic acid) and thus favouring a feeling of relaxation of the patient.
- the composition of the invention further comprises melatonin as naturally-occurring active ingredient.
- melatonin is the circadian rhythm regulation, thus favouring falling asleep and sleep continuity. Furthermore, since it has an antioxidant effect, it acts in general by lowering the oxidative stress and consequently it favours an alleviation of the anxious state disorders.
- composition according to the invention favours the recovery of psycho-physical well-being in patients who suffer from mood disorders, in particular from mood lowering, due to the synergistic and complementary action of the active ingredients contained therein.
- compositions in the form of food supplement favours a reduction of the state of anxiety, thus reducing both symptoms related to the emotional sphere, such as fear, apprehension and concern, and physical symptoms, such as palpitations, chest pains, shortness of breath and/or nausea.
- a further advantage of the present invention is that such composition may also have a beneficial effect on sleep disorders.
- composition described herein does not display certain side effects typical of the above-mentioned synthetic drugs administered to patients who suffer from mood disorders, such as depression.
- the formulations for the oral administration comprise for example capsules, tablets, powders, granules and gels.
- the active compounds can be mixed with different excipients, such as inert diluents, such as for example saccharose, lactose, starch or maltodextrin, sweetening agents, such as sorbitol, sucralose, steviol glycosides, flavors, anti-caking agents, such as silicon dioxide, lubricants, such as for example magnesium salts of saturated fatty acids, dyes, film-forming agents, microcrystalline cellulose, cellulose derivates, such as carboxymethylcellulose, ethyl cellulose, hydroxypropyl methylcellulose and thickening agents.
- inert diluents such as for example saccharose, lactose, starch or maltodextrin
- sweetening agents such as sorbitol, sucralose, steviol glycosides
- flavors anti-caking agents
- lubricants such as for example magnesium salts of saturated fatty acids
- dyes such as for example dyes, film-forming agents, microcrystalline cellulose
- the pharmaceutical preparations according the present invention can be produced by using conventional pharmaceutical techniques, as described in the different pharmacopoeias or in handbooks of the field, such as for example “Remington’s Pharmaceutical Sciences Handbook”, Mack Publishing, New York, 18th Ed., 1990.
- the average daily dosage of the composition according to the present invention depends on many factors, such as for example the patient’s conditions (age, weight, sex): the total dose of the active ingredients may vary in general from 240 mg to 533 mg per day, possibly divided into more than one administration.
- such a composition may be formulated in tablets that allow a multiphasic release of the active ingredients therein contained.
- such a formulation allows a release of the active ingredients at scheduled times to obtain a gradual beneficial and long- lasting effect.
- a further advantage is represented by the fact that the present formulation can favour a considerable reduction of the oxidative stress (at a systemic level) which is closely related to anxiety and/or depressive states, which are often characterized by insomnia.
- Figure 1 shows the release profiles over time of tablets according to the present invention immersed in a HC1 solution (pH 1.1) for 120 minutes and later immersed in a phosphate buffer 0.2 M (pH 6.8) solution for 3 hours.
- Figure 2 shows a bar graph of the scores according to the test DASS-21 obtained from each subject of group A before the treatment and after the treatment.
- the score difference (delta) between the score obtained before the treatment and that obtained after the treatment is further shown.
- Figure 3 shows a bar graph of the score averages according to the test D ASS-21 of group A obtained before the treatment and after the treatment.
- Figures 4A and 4B show two graphs which report the percentage distribution of the subjects of group A according to the test DASS-21 , in the score range 0-21 (no depressive traits) and in the score range 22-42 (moderate depression), respectively, before and after the treatment.
- Figure 5 shows a bar graph of the scores according to the test DASS-21 obtained from each subject of group B before the treatment and after the treatment.
- the score difference (delta) between the score obtained before the treatment and that obtained after the treatment is further shown.
- Figure 6 shows a bar graph of the score averages according to the test D ASS-21 of group B obtained before the treatment and after the treatment.
- Figures 7 A and 7B show two graphs which report the percentage distribution of the subjects of group B according to the test DASS-21 , in the score range 0-21 (no depressive traits) and in the score range 22-42 (moderate depression) before and after the treatment, respectively.
- Figure 8 shows a bar graph of the scores according to the test STAI-Y obtained from each subject of group A before the treatment and after the treatment.
- the score difference (delta) between the score obtained before the treatment and that obtained after the treatment is further shown.
- Figure 9 shows a bar graph of the averages of the scores according to the test STAI-Y of group A obtained before the treatment and after the treatment.
- Figures 10A and 10B show two graphs which report the percentage distribution of the subjects of group A according to the test STAI-Y, in the score range 20-40 (no significant anxiety problem) and in the score range 41-60 (physiological and moderate anxiety), before and after the treatment, respectively.
- Figure 1 1 shows a bar graph of the scores according to the test STAI-Y obtained from each subject of group B before the treatment and after the treatment.
- the score difference (delta) between the score obtained before the treatment and that obtained after the treatment is further shown.
- Figure 12 shows a bar graph of the averages of the scores according to the test STAI-Y of group B obtained before the treatment and after the treatment.
- Figure 13A and 13B show two graphs which report the percentage distribution of the subjects of group B according to the test STAI-Y, in the score range 20-40 (no significant anxiety problem) and in the score range 41-60 (physiological and moderate anxiety) and in the score range 61-80 (anxiety predominating in everyday life) before and after the treatment, respectively.
- the present invention describes a composition for the prevention and/or treatment of mood disorders and/or anxiety disorders.
- “mood disorders”, as used herein, means in particular the depressive symptoms and the pathologies therewith associated, such as for example the lowering of mood, sleep disorders, persistent sensation of sadness, difficulty in concentrating, increase or reduction of appetite.
- Physical symptoms determined by the depressive state among which for example tremor of the limbs, dry mouth, tachycardia, increased sweating and difficulty in swallowing, are further comprised.
- anxiety disorders or“states of anxiety”, as used herein, means in particular disorders related to the state anxiety and trait anxiety.
- the state anxiety is conceived as a particular experience, a feeling of insecurity, impotence in front of a perceived harm, which can lead to concern or escaping and avoiding.
- the trait anxiety consists of the tendency to perceive stressful situations as dangerous and threatening and to respond to the various situations with different intensity.
- This composition exclusively contains active ingredients of natural origin, namely saffron extract, magnolia extract and green tea extract and can optionally contain also L-theanine and melatonin.
- saffron extract means a Crocus sativus (stigmas) dry extract titrated in crocin and safranal (expressed as sum, at 3.5%).
- magnolia extract means a Magnolia officinalis (bark) dry extract titrated in honokiol (> 2%).
- green tea extract means a Camellia sinensis (green leaves) dry extract titrated in total catechins (> 60%) and epigallocatechin gallate (> 40%) and decaffeinated.
- composition as its active ingredients are all of natural origin, shows excellent tolerability and is substantially free of side effects, in particular of those side effects that are typical of the synthetic drugs that are usually administered to contrast mood disorders.
- composition comprises different active ingredients which have different effects and act in synergy with each other; for this reason, the composition of the invention favours a total recovery of the psycho-physical wellbeing of patients who suffer from sleep disorders, thus improving the mood and, at the same time, alleviating anxiety disorders and favouring falling asleep and sleep continuity.
- composition according to the present invention comprises: saffron extract, magnolia extract and green tea extract.
- the composition is formulated in tablets and is taken as food supplement with controlled release.
- the saffron extract obtained from the stigmas of such plant contains different compounds, among which safranal and crocins.
- crocins are the most abundant components in the saffron plant and can exist in different isoforms, the most abundant of which is alfa-crocin.
- These compounds are glycosylated carotenoids and have a quite particular structure; they are actually constituted by 20 carbon atoms with 2 carboxylic groups on the first carbon 1 (Cl) and on the sixteenth carbon (Cl 6).
- crocins in the saffron extract seems to be essential for the action of this extract in improving the mood in patients suffering from mood disorders.
- the saffron extract acts by means of the so-called “serotonergic action”, namely an inhibition mechanism of the serotonin reuptake at presynaptic nerve receptors, thus increasing the availability of this molecule in the spaces designated for the nervous transmission (synapses).
- the saffron extract is rich in carotenoids, it also shows an antioxidant and neuroprotective action, thus reducing the levels of the reactive oxygen species (ROS) in the organism.
- ROS reactive oxygen species
- Crocin is not directly absorbed but is hydrolysed in crocetin, which can be absorbed at the intestine .
- Crocetin has an interesting pharmacokinetics which significantly differs from that of the other known carotenoids naturally present in foods or contained in nutraceutical products, such as for example beta carotene, lutein and lycopene.
- crocetin is rapidly absorbed and its presence can be noticed in plasma around one hour after the administration reaching a peak at around 4 hours.
- Such a compound is characterized by a quite long half-life of 6-7 hours since, after its fast absorption, a phase of around 4 hours of slower and more gradual absorption follows.
- Crocetin is more hydrophilic and smaller than other carotenoids, therefore it is directly absorbed by the portal vein and therefrom it is distributed into the organism passing through the liver.
- Magnolia extract contains magnolol and honokiol, two phenolic compounds which act by the modulation of physiological mechanisms triggered by stress.
- Magnolia extract contributes to the reduction of sleep disorders, thus improving the sleep quality and favouring a perceivable decrease of the daily sleepiness.
- This extract as well exerts a strong GABAergic action which can be compared to that exerted by the benzodiazepines (the so-called hypno- inducing molecules), but which does not have the side effects thereof.
- Magnolol and honokiol modulate the GABA-A receptors of the cerebral limbic system, centre of emotions and feelings; this explains the calming and muscle-relaxant activity and the rebalancing activity of the sleep alterations. These effects determine a perceivable reduction of the mood disorder, irritability, anxiety symptoms and also of sleep disorders.
- Magnolia extract pharmacokinetics
- magnolia dry extract After the oral administration of magnolia dry extract, it has been observed that the main metabolite is the conjugate of hydroxy-magnolol. Furthermore, it has been observed that the magnolia extract naturally contains around 94% of magnolol and 1.5% of honokiol. Consequently, it is believed that the calming effect attributed to this extract is due to the presence of magnolol.
- Green tea extract contains epigallocatechin gallate (EGCG) and catechins, which are antioxidant molecules that contribute to reduce the oxidative stress, a target specifically studied to reduce anxiety conditions, depression and sleep disorders.
- EGCG epigallocatechin gallate
- catechins which are antioxidant molecules that contribute to reduce the oxidative stress, a target specifically studied to reduce anxiety conditions, depression and sleep disorders.
- the possible mechanism of action of the EGCG at a cerebral level occurs on the receptor GABA-A through the carbonyl portion of the molecule, which is generally common to the flavonoids.
- This binding has a sedative effect in conditions of acute stress, reducing the vigilance time (vigil) and exerting a sedative and hypnotic action.
- the pharmacokinetic profile of polyphenols after oral ingestion is very interesting because the original compounds do not appear in the circulation but phase-II metabolites do, and their presence in circulation, after the consumption with foods, rarely exceed the nanomolar concentrations .
- flavonoids are typically ingested with the diet in the glycosylated form and their absorption is associated with a cut and release of the aglycone as a result of the action of enzymes located on the apical wall of the small intestine.
- the cleavage enzymes have affinities to the specific chemical structures and the bonds between the sugar unit and the aglyconic part. The latter could be absorbed by passive diffusion through the epithelial cells as a result of the increase of its lipophilicity.
- Another hydrolytic stage could be mediated by cytosolic beta-glycosidase inside the epithelial cells. Therefore, in this case, the polar glycoside would be transferred into the cell through the involvement of the transfer of the sodium-dependent glucose transporter type 1 (SGLT1).
- SGLT1 sodium-dependent glucose transporter type 1
- the aglyconic component undergoes a phase II metabolism, , forming sulphate, glucuronate and/or methylated conjugates through the correspondent enzymes involved in these reactions (SULTs, UGT, COMTs).
- L-theanine amino acid affects the levels of noradrenaline, serotonin and dopamine. In particular, it acts as antagonist of the glutamic acid, an excitatory neurotransmitter, thus reducing the state of anxiety.
- L-theanine is rapidly absorbed at the intestinal level and distributed in the tissues and, in particular, it very easily trespasses the human blood- brain barrier through the transport system of the neutral amino acids.
- L-theanine amino acid reaches the maximum plasmatic concentration between 30 minutes and 2 hours after the administration.
- the main catabolite is ethylamine, which is excreted and observed at the renal level.
- Such amino acid produces different variations in the cerebral biochemistry and in particular in the synthesis or inhibition of some neuro transmitters .
- L-theanine in fact increases the levels of GABA, responsible for the feeling of relaxation and the so-called “wellbeing effect”, and it exerts a significant effect on the release of dopamine and serotonin, which are closely related to the mnemonic and learning abilities.
- the amino acid acts by reducing the glutamate release from the presynaptic neurons, which acts as powerful excitatory neuro transmitter and increases the cerebral alpha waves which induce relaxation.
- Melatonin is a hormone which is mainly released by the hypophyseal or pineal gland located at the base of the brain.
- Serotonin is one of the main precursors of melatonin, whereby in a patient suffering from mood disorders, in which the concentration of serotonin is quite low, the concentration of melatonin is also reduced, therefore causing sleep disorders or worsening them.
- the melatonin supplements are thus administered to these patients in order to compensate for the deficiency of melatonin naturally produced by the organism and to regulate the circadian rhythm.
- melatonin also carries out an antioxidant action, protecting the cells from the action of free radicals, whose concentration increases in stress and insomnia conditions.
- Melatonin has an oral bioavailability characterized by a high interindividual variability: 3%-76%.
- the oral bioavailability parameter is significantly affected by the extent of the intestinal absorption and the extent of the metabolic elimination processes.
- the absorbed melatonin undergoes a significant hepatic first pass metabolism of: phase I: hydroxylation from cytochromes; phase II: conjugation with sulphate or hyaluronic acid.
- the absorption can even diminish by 50% in the elderly subject.
- Melatonin is distributed in the peripherical tissues due to its lipophilicity and is eliminated in the form of metabolites through urine, saliva and milk.
- the half-life time of melatonin is around 30-60 minutes, whereby it does not undergo accumulation phenomena.
- the above-mentioned composition is preferably formulated in tablet and administrated as food supplement.
- This tablet is structured so as to allow a release programmed over time of the single active ingredients therein contained.
- this tablet has an outer coating and an inner part consisting of a core which comprises in turn a gastro-resistant granulate inside it.
- the outer coating consists of a film comprising melatonin as active ingredient; the core comprises the green tea extract and L-theanine and the granulate comprises the saffron extract and the magnolia extract.
- Such tablet structure allows to obtain a release in subsequent phases of the different active ingredients, thus allowing obtaining a gradual and long-lasting beneficial effect.
- melatonin is the first active ingredient released in the organism, since it is comprised in the most external part of the tablet.
- the tablet preparation method involves several steps.
- the first step involves the preparation of a gastro-resistant granulate, by mixing the saffron extract and the magnolia extract with polyvinylpyrrolidone and microcrystalline cellulose, and adding then a granulation liquid and the shellac ammonium salt.
- the gastro-resistant granulate obtained as above described is mixed with the following ingredients, which have been previously singularly sifted: green tea extract, L-theanine, cross-linked sodium carboxymethylcellulose, microcrystalline cellulose and silicon dioxide; then, the flowability and density of the mixture is verified.
- the core After the core has been prepared, it is pressed, thus obtaining non-coated tablets with weight of around 1 g each one.
- the last preparation step is the coating step.
- a coating film water and glycerine are mixed to which white Sepifilm® LP 770 (made of hydroxypropyl methylcellulose, microcrystalline cellulose, fatty acids and titanium dioxide), a dye, glycerine and melatonin are added. After mixing for at least 40 min, the possible formation of lumps is controlled, and then a filtration is performed until a homogeneous mixture is obtained.
- white Sepifilm® LP 770 made of hydroxypropyl methylcellulose, microcrystalline cellulose, fatty acids and titanium dioxide
- a dye, glycerine and melatonin are added. After mixing for at least 40 min, the possible formation of lumps is controlled, and then a filtration is performed until a homogeneous mixture is obtained.
- the quantity of used purified water is the one necessary and sufficient for the granulation.
- the tablets obtained according to the method of the present invention have been tested in vitro for determining whether they had been structured so as to allow a controlled release over time of the active ingredients contained therein.
- the first released active ingredient is melatonin, which is comprised in the outer coating film, followed by L-theanine (comprised in the core) and by the saffron extract (comprised in the gastro-resistant granulate).
- a pilot clinical trial has been carried out involving 24 healthy volunteers to evaluate both the previous presence of mood and anxiety symptoms and the possible improvement thereof due to the intake of a tablet containing saffron extract, magnolia extract, green tea extract and excipients as described in the present invention.
- the aim of the present trial was that of demonstrating that saffron at a lower dosage, and associated with other naturally occurring ingredients, such as the magnolia extract and the green tea extract, which are per se not known to influence the mood, had a synergistic effect on the improvement of the depressive symptoms and possibly also of the anxiety symptoms, compared to the effect of the saffron extract used alone.
- Group A 9 subjects (5 males and 4 females), who took a tablet according to the invention described in Table 1.
- Group B 1 1 subjects (3 males and 8 females), who took a tablet according to patent application ES 2573542 described in Table 1.
- the posology was of 1 tablet a day before bedtime, for 24 consecutive days .
- the tablet obtained according to the present invention contains three naturally-occurring active ingredients: green tea extract, saffron extract and magnolia extract. This tablet was administered to group of volunteers “A”.
- the tablet obtained according to patent application ES 2573542 only contains saffron extract as naturally-occurring active ingredient. This tablet was administered to group of volunteers“B”.
- the questionnaire for depression sumytoms In order to gather useful informations before and after the trial and to quantitatively compare them with each other, a literature-based questionnaire has been worked out. .
- DASS-21 depression Anxiety Stress Scales-21
- The“DASS-21” questionnaire is composed as shown in Table 2:
- Table 2 Questions, answers and score of the“DASS-21” questionnaire
- Subject E who did not report a numeric improvement, seems to confirm the score obtained before the treatment, which could be explained as a variability which is subjective and not indicative of an exacerbation.
- subjects B, D and I had an initial score falling within the score range“22-42”, corresponding to“lowering of mood and moderate depression”. Their score after the treatment was considerably reduced, namely:
- the average score of group A according to the results obtained from the DASS-21 test decreased by 10.22 points (- 57.84%) after the treatment, indicating an objective perception of the mood improvement by the participants.
- Figure 4B shows that all participants fall within the score range“0-21” after the treatment, whereas around 33% of the participants was in the score“22-42” ( Figure 4A) before the treatment.
- the 1 1 subjects of group B started from an average score of the DASS-21 questionnaire equal to 15.27, corresponding to“no depression”.
- Figures 7 A and 7B show that the number of subjects with score“0-21” (around 91%) considerably increased after the treatment with the tablet of the present invention, compared to that observed before the treatment (around 64%).
- composition of the present invention containing saffron extract (in a quantity equal to 15 mg), magnolia extract and green tea extract has a synergic action on the depression symptoms compared to the known composition only containing saffron (in a quantity equal to 28 mg) as active ingredient.
- STAI-Y the self-assessment questionnaire commonly known as“STAY TRAIT ANXIETY INVENTORY” (STAI-Y) has been used as reference.
- the STAI-Y is a tool easy to apply and interpret for detecting and measuring anxiety, both for psycho-diagnostic purposes and for verifying efficacy and benefits of the psychotherapy or another treatment.
- the questionnaire is formed by 40“items”, which the subject has to answer to in terms of intensity (from“hardly never” to“almost always”) .
- the items are grouped into two scales focused on how the subjects usually feel or on what they instead feel in particular moments.
- State anxiety wherein anxiety is understood as a particular experience, a feeling of insecurity, impotence in respect of a perceived damage which can lead to concern or to escape and avoidance.
- the state anxiety is measured through questions referring to how the subject feels at the moment of the questionnaire submission.
- Table 3 Evaluation scale for the state anxiety.
- Table 4 Evaluation scale for trait anxiety.
- the 9 subjects of group A started from an average score of the STAI-Y questionnaire (adapted according to the above simplification of the Applicant) equal to 44.33 corresponding to“a physiological, moderate, manageable anxiety”.
- the average score of STAI-Y after the treatment decreased by 9.44 points (-21.29%), passing from the intermediate score range to the desired score range ( Figure 9).
- the 1 1 subjects of group B started from an average score of the STAI-Y questionnaire equal to 47.45 corresponding to“a physiological, moderate, manageable anxiety”.
- subject R The data related to subject R is interesting, since an increase of 15 difference points is observed, which can be indicative of a worsening condition.
- subject S in this case like in group A, the increase is not to be considered as worsening, but it rather reflects the subjective variability.
- Subject V substantially confirms the initial condition without any improvements.
- Figure 13 A shows the distribution of the subjects of group B according to the STAI score before the treatment: 18% of patients are in the score 20-40.
- Figure 13B shows the distribution of the same subjects after the treatment with a tablet comprising the composition described in known document ES2573542.
- composition of the present invention containing saffron extract (in a quantity equal to 15 mg), magnolia extract and green tea extract has a synergic action on the anxiety disorders compared to the known composition only containing saffron (in a quantity equal to 28 mg) as an active ingredient.
- Such a composition is therefore effective not only for the treatment of depression disorders but also for the treatment of anxiety disorders.
- MINERVA GINECOL 63: 1-7.
- Umigai et al., 201 1 The pharmacokinetic profile of crocetin in healthy adult human volunteers after a single oral administration. Phytomedicine 18; 575-578.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
L'invention concerne une composition comprenant un extrait de safran, un extrait de magnolia et un extrait de thé vert, ainsi qu'éventuellement de la L-théanine et de la mélatonine, destinée à être utilisée dans la prévention et le traitement de troubles de l'humeur et/ou de troubles de l'anxiété ; une formulation pharmaceutique ou de complément alimentaire appropriée pour une administration par voie orale, pour la prévention et le traitement de troubles de l'humeur et/ou de troubles de l'anxiété, comprenant la composition mentionnée ci-dessus et au moins un excipient pharmaceutiquement ou nutritionnellement acceptable est également décrite.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT102018000004108A IT201800004108A1 (it) | 2018-03-29 | 2018-03-29 | Composizione a base naturale per l’uso nel trattamento dello stress cronico caratterizzato da disturbi dell’umore e/o ansia |
IT102018000004108 | 2018-03-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019185439A1 true WO2019185439A1 (fr) | 2019-10-03 |
Family
ID=62875090
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2019/057055 WO2019185439A1 (fr) | 2018-03-29 | 2019-03-21 | Composition de base naturelle destinée à être utilisée dans le traitement d'un stress chronique, caractérisé par des troubles de l'humeur et/ou de l'anxiété |
Country Status (2)
Country | Link |
---|---|
IT (1) | IT201800004108A1 (fr) |
WO (1) | WO2019185439A1 (fr) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210089350A (ko) * | 2020-01-08 | 2021-07-16 | 삼육대학교산학협력단 | 신이 추출물 또는 분획물을 포함하는 수면 유도 및 개선용 조성물 |
WO2021209455A1 (fr) * | 2020-04-15 | 2021-10-21 | Activ'inside | Composition pour ameliorer les fonctions cognitives |
WO2023283108A1 (fr) * | 2021-07-05 | 2023-01-12 | Celesta Company LLC | Composition pour favoriser le sommeil réparateur et procédés de fabrication et d'utilisation de celle-ci |
IT202200000842A1 (it) * | 2022-01-19 | 2023-07-19 | Kolinpharma S P A | Composizione multicomponente comprendente epigallocatechina gallato, ed estratto secco di zafferano, e suo uso nella prevenzione e nel trattamento del parkinson |
WO2024084290A1 (fr) * | 2022-10-21 | 2024-04-25 | Kolinpharma S.P.A. | Composition destinée à être utilisée dans une methode de prévention et de traitement d'un déclin cognitif et/ou de formes de démence |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050208156A1 (en) | 2002-03-26 | 2005-09-22 | Lichtwer Pharma Gmbh | Plants extracts and the use thereof |
US20060018975A1 (en) | 2004-07-20 | 2006-01-26 | Talbott Shawn M | Methods and compositions for weight management and mood enhancement |
US20110014277A1 (en) | 2006-06-21 | 2011-01-20 | Harlan Clayton Bieley | Smoking Cessation With Body Weight Maintenance And Nutritional Supplement |
ES2573542A1 (es) | 2016-04-18 | 2016-06-08 | Pharmactive Biotech Products, S.L. | Empleo de un nuevo extracto de azafrán para la prevención de trastornos del estado de ánimo relacionados con la depresión |
US20170239312A1 (en) | 2013-09-03 | 2017-08-24 | Nse Products, Inc. | Weight management systems and related methods |
-
2018
- 2018-03-29 IT IT102018000004108A patent/IT201800004108A1/it unknown
-
2019
- 2019-03-21 WO PCT/EP2019/057055 patent/WO2019185439A1/fr active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050208156A1 (en) | 2002-03-26 | 2005-09-22 | Lichtwer Pharma Gmbh | Plants extracts and the use thereof |
US20060018975A1 (en) | 2004-07-20 | 2006-01-26 | Talbott Shawn M | Methods and compositions for weight management and mood enhancement |
US20110014277A1 (en) | 2006-06-21 | 2011-01-20 | Harlan Clayton Bieley | Smoking Cessation With Body Weight Maintenance And Nutritional Supplement |
US20170239312A1 (en) | 2013-09-03 | 2017-08-24 | Nse Products, Inc. | Weight management systems and related methods |
ES2573542A1 (es) | 2016-04-18 | 2016-06-08 | Pharmactive Biotech Products, S.L. | Empleo de un nuevo extracto de azafrán para la prevención de trastornos del estado de ánimo relacionados con la depresión |
WO2017182688A1 (fr) | 2016-04-18 | 2017-10-26 | Pharmactive Biotech Products, S.L. | Extrait de safran et son utilisation pour prévenir les troubles de l'humeur associés à la dépression |
Non-Patent Citations (35)
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210089350A (ko) * | 2020-01-08 | 2021-07-16 | 삼육대학교산학협력단 | 신이 추출물 또는 분획물을 포함하는 수면 유도 및 개선용 조성물 |
KR102287719B1 (ko) * | 2020-01-08 | 2021-08-09 | 삼육대학교산학협력단 | 신이 추출물 또는 분획물을 포함하는 수면 유도 및 개선용 조성물 |
WO2021209455A1 (fr) * | 2020-04-15 | 2021-10-21 | Activ'inside | Composition pour ameliorer les fonctions cognitives |
FR3109298A1 (fr) * | 2020-04-15 | 2021-10-22 | Activ'inside | Composition pour améliorer les fonctions cognitives |
WO2023283108A1 (fr) * | 2021-07-05 | 2023-01-12 | Celesta Company LLC | Composition pour favoriser le sommeil réparateur et procédés de fabrication et d'utilisation de celle-ci |
US20230039674A1 (en) * | 2021-07-05 | 2023-02-09 | Celesta Company LLC | Composition for Promoting Restful Sleep and Methods of Making and Using the Same |
IT202200000842A1 (it) * | 2022-01-19 | 2023-07-19 | Kolinpharma S P A | Composizione multicomponente comprendente epigallocatechina gallato, ed estratto secco di zafferano, e suo uso nella prevenzione e nel trattamento del parkinson |
WO2023139514A1 (fr) * | 2022-01-19 | 2023-07-27 | Kolinpharma S.P.A. | Composition à composants multiples comprenant du gallate d'épigallocatéchine et un extrait sec de safran, et son utilisation dans la prévention et le traitement de la maladie de parkinson |
WO2024084290A1 (fr) * | 2022-10-21 | 2024-04-25 | Kolinpharma S.P.A. | Composition destinée à être utilisée dans une methode de prévention et de traitement d'un déclin cognitif et/ou de formes de démence |
Also Published As
Publication number | Publication date |
---|---|
IT201800004108A1 (it) | 2019-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2021266209B2 (en) | Theacrine-based supplement and method of use thereof | |
WO2019185439A1 (fr) | Composition de base naturelle destinée à être utilisée dans le traitement d'un stress chronique, caractérisé par des troubles de l'humeur et/ou de l'anxiété | |
US11707465B2 (en) | Theacrine-based supplement and method of use thereof in a synergistic combination with caffeine | |
CA2709958C (fr) | Utilisation d'un extrait de feuilles de ginkgo biloba | |
JP7461066B2 (ja) | スポーツ上の動作を強化するための組成物 | |
ES2681996A2 (es) | Composiciones para reducir el apetito y el ansia,potenciar la saciedad, mejorar el estado de animo y reducir el estres. | |
US20230190757A1 (en) | Enhanced caffeinated beverage composition | |
KR20240004452A (ko) | 1-메틸크산틴-기반 생체활성 조성물 및 이의 사용 방법 | |
EP3651770B1 (fr) | Supplément à base de théacrine et son procédé d'utilisation dans une combinaison synergique avec de la caféine | |
JP6698034B2 (ja) | 冷え症等の全身症状改善用経口組成物 | |
US20220160808A1 (en) | Anti-Psychotic Composition and Treatment Methods | |
WO2021137926A1 (fr) | Composition de boisson caféinée améliorée | |
WO2021123071A1 (fr) | Composition | |
FR2989557A1 (fr) | Nouvelles compositions alimentaires et leur mode de realisation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19714141 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 19714141 Country of ref document: EP Kind code of ref document: A1 |